Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a report released on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings per share of ($0.70) for the year, up from their previous forecast of ($0.72). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Several other equities research analysts have also issued reports on GOSS. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Price Performance

GOSS opened at $1.28 on Wednesday. The firm has a market capitalization of $290.84 million, a P/E ratio of -4.00 and a beta of 1.86. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55. The company has a fifty day moving average price of $1.18 and a 200-day moving average price of $0.99. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analysts’ expectations of $7.02 million.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently added to or reduced their stakes in the company. Graham Capital Management L.P. bought a new position in shares of Gossamer Bio during the 4th quarter valued at about $32,000. Fullcircle Wealth LLC purchased a new stake in Gossamer Bio in the fourth quarter worth approximately $43,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the third quarter worth approximately $67,000. Velan Capital Investment Management LP purchased a new position in shares of Gossamer Bio during the fourth quarter worth approximately $68,000. Finally, Bank of America Corp DE boosted its stake in shares of Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after purchasing an additional 43,866 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.